Impala Nordic comments the news that Brain+ A/S (“Brain+” or the “Company”) has signed an agreement to deploy Ayla in one of the UK’s largest primary care practices within the UK National Health Service (“NHS”). We view this agreement as a landmark step for Ayla’s UK adoption.

This will be the first deployment of Ayla, and the first use of Cognitive Stimulation Therapy (“CST”), in NHS primary care. The seven week pilot at a General Practitioner practice serving more than 28 000 patients is intended to demonstrate the benefit of introducing Ayla-delivered CST earlier in the pathway. A recent Post Market Clinical Follow-up Study (“PMCF”) pilot conducted by the Company in two UK care homes reported nearly 50 % improvement in cognitive outcomes. The agreement complements the primary near-term cash driver in private care homes, opening a long-term NHS growth channel, and it shows the Company’s ability to turn relationship-building into action.

Read our full comment here.